New immune therapy targets deadliest brain tumors
NCT ID NCT04214392
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 24 times
Summary
This early-phase trial tests a new type of immune cell therapy (CAR T cells) designed to target and kill glioblastoma, an aggressive brain cancer that has returned or worsened. The therapy uses a special targeting domain (chlorotoxin) to seek out cancer cells. The study involves 19 participants and focuses on finding the safest dose and understanding side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.